TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.89 USD
+0.01 (0.27%)
Updated Aug 30, 2024 02:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TXMD 1.89 +0.01(0.27%)
Will TXMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TXMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TXMD
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TXMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Other News for TXMD
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
TherapeuticsMD: Q2 Earnings Snapshot
TherapeuticsMD Announces Second Quarter 2024 Financial Results
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
Therapeutics MD GAAP EPS of -$0.09